資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/65262
|
| 題名: | Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung. |
| 作者: | 蕭世欣
Shih-Hsin Hsiao, Wan-Ting Chen, Chi-Li Chung, Yu-Ting Chou, Sey-En Lin, Shiao-Ya Hong, Jer-Hwa Chang, Tzu-Hao Chang, Li-Nien Chien |
| 貢獻者: | 醫學系內科學科胸腔內科 |
| 關鍵詞: | Keywords: 5-year survival rate;early-stage non-small-cell lung cancer;overall survival;platinum-based adjuvant chemotherapy;treatment failure-free survival. |
| 日期: | 2022-05 |
| 上傳時間: | 2025-03-30 15:39:06 (UTC+8) |
| 摘要: | Abstract
Background and purpose: Although cytotoxic platinum-based adjuvant chemotherapy (pACT) has been recommended for patients with completely resected early-stage (ES) non-small-cell lung cancer (ES-NSCLC), therapeutic regimens for NSCLC have evolved in the past two decades. The study was aimed to examine the effectiveness of postoperative pACT for resected ES-NSCLC patients with squamous cell carcinoma (SCC) or adenocarcinoma (ADC) according to real-world data.
Methods and patients: Inverse probability treatment weighting (IPTW) was used to adjust baseline characteristics between the group receiving pACT and those not receiving any treatment (observation, OBS) within 3 months after curative surgery. Cox regression models were used to compare overall survival (OS) and treatment failure-free survival (TFS) between the groups.
Results: Of 31,208 patients with ES-NSCLC, 4700 undergoing complete tumor resection were eligible, with a mean follow-up period of 4.5 years. The pACT (n = 2347) and OBS (n = 2353) groups were well-balanced after IPTW. The median OS differed between the pACT and OBS groups (77.2 vs. 75.5 months, adjusted hazard ratio [aHR] = 0.87, 95% confidence interval [CI] = 0.79-0.95, p = 0.003), and the 5-year survival rates were 58.2% and 55.3%, respectively (p < 0.001). In the SCC group, pACT was superior to OBS in OS (75.0 vs. 57.4 months, aHR = 0.74, 95% CI = 0.62-0.88, p = 0.001) and TFS (32.7 vs. 21.8 months, aHR = 0.74, 95% CI = 0.63-0.86, p < 0.001). Both OS and TFS did not differ between two groups in those with ADC.
Conclusion: Real-world data indicated that pACT confers a survival benefit for resected ES-NSCLC patients with SCC but not ADC, which needs to be verified by a large sample of randomized controlled studies. |
| 關聯: | Cancer Med. 2022 May;11(10):2067-2078 |
| 描述: | 【111-2 升等】臺北醫學大學教師升等專門著作
職別：專任教師
送審等級：副教授
著作送審 |
| 資料類型: | article |
| 顯示於類別: | [教師升等送審著作] 111
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 3 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
